Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 3, 2007, Pages 264-270

  Yao, Min ^a,c   Luo, Pifu ^a   Hoffman, Henry T ^a   Chang, Kristi ^a   Graham, Michael M ^a   Menda, Yusuf ^a   Tan, Huaming ^b   Buatti, John M ^a  

^a UNIVERSITY OF IOWA HEALTH CARE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

FDG PET; Head and neck cancer; Neck dissection; Radiation; Residual lymph node

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE; LYMPHADENOPATHY; MALE; NECK DISSECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; SENSITIVITY AND SPECIFICITY; ULTRASOUND;

ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 34250002270     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000257611.65290.aa     Document Type: Article

References (29)

1. Barkley HT Jr, Fletcher GH, Jesse RH, et al. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. Am J Surg. 1972;124:462-467.
2. Mendenhall WM, Million RR, Cassisi NJ. Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. Int J Radiat Oncol Biol Phys. 1986;12:733-740.
3. Peters LJ, Weber RS, Morrison WH, et al. Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. Head Neck. 1996;18:552-559.
4. Chan AW, Ancukiewicz M, Carballo N, et al. The role of postradiotherapy neck dissection in supraglottic carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:367-375.
5. Johnson CR, Silverman LN, Clay LB, et al. Radiotherapeutic management of bulky cervical lymphadenopathy in squamous cell carcinoma of the head and neck: is postradiotherapy neck dissection necessary? Radiat Oncol Invest. 1998;6:52-57.
6. Clayman GL, Johnson CJ 2nd, Morrison W, et al. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg. 2001;127:135-139.
7. Ojiri H, Mendenhall WM, Stringer SP, et al. Post-RT CT results as a predictive model for the necessity of planned post-RT neck dissection in patients with cervical metastatic disease from squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:420-428.
8. Narayan K, Crane CH, Kleid S, et al. Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: for some or for all? Head Neck. 1999;21:606-613.
9. Schwartz DL, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003;129:1173-1178.
10. Teknos TN, Rosenthal EL, Lee D, et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck. 2001;23:1056-1060.
11. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys. 2004;60:1410-1418.
12. Mukherji SK, Wolf GT. Evaluation of head and neck squamous cell carcinoma after treatment. AJNR Am J Neuroradiol. 2003;24:1743-1746.
13. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651-658.
14. Kunkel M, Forster GJ, Reichert TE, et al. Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer. 2003;98:2257-2265.
15. Yao M, Graham MM, Hoffman HT, et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1001-1010.
16. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005;27:175-181.
17. Rogers JW, Greven KM, McGuirt WF, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys. 2004;58:694-697.
18. Yao M, Dornfeld KJ, Buatti JM. In regard to Lee et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. (Int J Radiat Oncol Biol Phys. 2003;57:49-60). Int J Radiat Oncol Biol Phys. 2004;58:1639; author reply 1639-1640.
19. Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942-946.
20. Ryan WR, Fee WE Jr, Le QT, et al. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645-650.
21. Ahmed N, Kansara M, Berridge MV. Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 affinity for glucose is enhanced during the respiratory burst. Biochem J. 1997;327:369-375.
22. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
23. El-Haddad G, Zhuang H, Gupta N, et al. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34:313-329.
24. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am. 2005;43:121-134.
25. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med. 1998;28:352-358.
26. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
27. Koike I, Ohmura M, Hata M, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys. 2003;57:1231-1238.
28. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991-999.
29. Radiation Therapy Oncology Group. A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. RTOG-0522. Protocol activated 11/22/2005. http://www.rtog.org/members/protocols/0522/0522.pdf.